Fresenius Group Overview

Investors

Fresenius Investment Highlights

 

  • Diversified revenue and earnings base with four strong business segments

  • Leading positions in non-cyclical markets with predictable growth

  • Industry-leading organic growth in all business segments

  • Strong earnings performance and cash flow generation

  • Attractive shareholder returns

  • Prudent financial management

 

"In the third quarter, Fresenius again achieved healthy sales growth and drove earnings growth even a touch stronger. Fresenius Kabi, Fresenius Vamed and Quirónsalud delivered a truly excellent performance. At the same time, Fresenius Medical Care and our German Helios hospitals will enhance their efforts to further improve and adapt to changing market conditions. From an overall position of strength, we are in the closing stretch for yet another record year."
(Stephan Sturm, Chairman of the Management Board)

News

  • Brief News
    Fresenius wins award for compensatory time account calculator

    Fresenius has been awarded the HR Excellence Award 2018 in the Compensation & Benefits category for the global healthcare group’s compensatory time account calculator. This calculator enables employees to quickly and transparently access information on time off that they have banked, options to take leave for continuing education or to care for family members, and possible early retirement. The HR Excellence Awards have been presented by Human Resources Manager magazine since 2012 to recognize outstanding projects in personnel management.

    December 14, 2018Fresenius
    Brief News
    Fresenius Kabi launches Omegaven® in the U.S.

    Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.

    December 10, 2018Fresenius Kabi
  • Brief News
    PWC proposed as auditor for 2020

    The Supervisory Board of Fresenius SE & Co. KGaA has decided to propose PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2020. The shareholders will decide on the appointment at the Annual General Meeting in 2020. New regulations provide for a regular rotation of the auditor, so Fresenius was not able to extend the existing mandate of KPMG AG Wirtschaftsprüfungsgesellschaft.

    December 10, 2018Fresenius
    Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019
    December 06, 2018Fresenius
  • Brief News
    Fresenius Kabi receives FDA Drug Shortage Assistance Award

    Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA). The FDA recognized the role Fresenius Kabi played in helping mitigate a shortage of IV saline, specifically Sodium Chloride Injection USP, 0.9% in bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria.  The hurricane devastated Puerto Rico, where many companies produce medicines for U.S. hospitals.

    December 03, 2018Fresenius Kabi
    Brief News
    Fresenius Vamed wins awards for spa and wellness facilities

    VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2018” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Villas, Aqua Dome Therme Längenfeld, Therme Laa Hotel & Spa, all in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.

    November 26, 2018Fresenius Vamed
  • Brief News
    Fresenius training programs among the best in Germany

    A recent study places Fresenius among the top 500 companies in terms of career training programs in Germany. Criteria used for judgement were the quality of supervision, in-house training, company engagement, success rate and innovative teaching methods. The companies were rated by the business magazine Capital and the internet portal, ausbildung.de. Fresenius received a best possible five-star rating for its on-the-job training and dual-studies, a combination of theory and on-the-job training, programs. The company trains more than 4,000 apprentices and dual-studies interns.

    November 19, 2018Fresenius
    Fresenius in Q3/18 with continued strong Group earnings growth in constant currency
    October 30, 2018Fresenius
  • Brief News
    Fresenius Helios acquires private hospital operator in Colombia, expanding presence in Latin America

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has acquired Clínica Medellín and entered the attractive private hospital market in Colombia. Clínica Medellín operates two centrally located hospitals in Medellín, a major city of 2.5 million people. The two facilities have a total of about 185 beds. The total investment for Clínica Medellín is more than €50 million. Following Quirónsalud's entry into Peru last year, this is another step in strengthening the company’s presence in Latin America’s growing and consolidating hospital markets. Fresenius Helios expects the transaction to close in Q1 2019, pending anti-trust and regulatory clearance.

    October 30, 2018Fresenius Helios
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Arsenic Trioxide Injection is the newest addition to the company’s oncology portfolio.

    October 26, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV drug in the US

    Fresenius Kabi HYDROmorphone Hydrochloride injection is a new offering for the company, expanding its analgesia and anesthesia portfolio. It is available in six single-dose vial presentations.

    October 24, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi launches Palonosetron in prefilled syringe in the U.S.

    Palonosetron Hydrochloride Injection is now available in the U.S. and is the newest product in the company’s Simplist™ prefilled syringe portfolio.  It is an antiemetic used to manage chemotherapy-induced nausea and vomiting. Fresenius Kabi is the first company to offer U.S. customers Palonosetron Hydrochloride in a ready-to-administer syringe.

    October 22, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches Heparin in freeflex® container in the U.S.

    Fresenius Kabi has launched Heparin Sodium injection in ready-to-administer non-DEHP freeflex® bags, expanding the company’s critical care portfolio. Fresenius Kabi offers a comprehensive portfolio of Heparin Sodium in the U.S. with multiple vial presentations, a pre-filled syringe and bag presentations.

    October 19, 2018Fresenius Kabi
    Fresenius Kabi reaches a global agreement with AbbVie
    October 18, 2018Fresenius Kabi
  • Fresenius confirms and narrows Group guidance for FY/18 and publishes preliminary results for Q3/18
    October 16, 2018Fresenius
    Brief News
    Fresenius Kabi opens compounding center in Canada

    Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.

    October 16, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi biosimilar candidate meets primary endpoints in the two pivotal clinical studies

    Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.

    October 09, 2018Fresenius Kabi
    Brief News
    2019 DRG inflator for German hospitals set at 2.65%

    The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.

    September 17, 2018Fresenius Helios
  • Brief News
    Fresenius Helios opens new hospital in Cordoba

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.    

    September 17, 2018Fresenius Helios
    Brief News
    Fresenius Helios opens emergency unit in eastern Germany

    Fresenius Helios has opened a new emergency unit at Helios Hospital Leisnig, in the eastern German state of Saxony. It contains four modern examination rooms and a specially equipped reanimation room, which will enable the hospital to provide even better care for its emergency patients, who now number some 10,000 annually. Architecturally optimized for medical processes and procedures, the new emergency unit was built in only 12 months. It required an investment by Fresenius Helios of about €1 million.

    August 28, 2018Fresenius Helios
  • Fresenius posts strong second quarter and confirms Group guidance – Continued net income growth – EBIT outlook raised for Fresenius Kabi
    July 31, 2018Fresenius
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Atropine Sulfate Injection further expands the company's anesthesia and analgesia portfolio.

    July 19, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Glycopyrrolate Injection is the newest addition to the company’s anesthesia and analgesia portfolio. 

    July 18, 2018Fresenius Kabi
    Brief News
    Fresenius Helios to partner with first online medical studies program

    Fresenius Helios will take responsibility for practical instruction as part of the first worldwide digitalized medical studies program. The new course of study meets European certification standards and will start in the winter semester 2018/2019 at the EDU College of Medicine, Malta. Theoretical components of a bachelor’s and follow-on master’s program will be available solely via an online platform. Students will be networked into learning communities taught by faculty. About one-third of the course is practical instruction that will take place in hospitals operated by Fresenius Helios in Germany. The program initially will be limited to 75 students. The long-term goal is up to 3,000 students.

    July 03, 2018Fresenius Helios
  • Brief News
    Fresenius Kabi expanding operations at UK site

    Fresenius Kabi is expanding its production and warehouse capacity in Runcorn, England, to meet increasing demand in United Kingdom’s homecare market and from UK and Ireland hospitals. The expansion’s first stage will be a new distribution and operations center, scheduled to open in early 2019. A second services unit for producing aseptically compounded parenteral nutrition products will be completed by 2020. Fresenius Kabi will invest over €9 million in the expansion.

    June 27, 2018Fresenius Kabi
    Fresenius Helios Capital Markets Day: Cross-border knowledge exchange creates basis for further growth
    June 08, 2018Fresenius Helios
  • Fresenius transfers inpatient rehabilitation business from Fresenius Helios to Fresenius Vamed
    June 06, 2018Fresenius Helios
    Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency
    May 03, 2018Fresenius
  • Brief News
    Fresenius Helios hospital gets highest rating in Spain

    Jiménez Díaz Foundation University Hospital in Madrid has again been awarded the EFQM Recognized for Excellence award with the maximum five stars, this time also receiving the highest rating of any hospital in Spain. The 667-bed facility earned more than 650 points on the rating scale used by the European Foundation for Quality Management during a comprehensive management and process evaluation earlier this year. In the award presentation, the EFQM cited Jiménez Díaz Foundation University Hospital’s intensive focus on patient care, as well as its continuous improvements in treatments and the use of medical technology. This leading teaching hospital is part of the Quirónsalud group, the Spanish unit of Fresenius Helios.

    April 27, 2018Fresenius Helios
    Fresenius terminates merger agreement with Akorn
    April 22, 2018Fresenius Kabi
Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

Please enter your first name.
Please enter your last name.
Please enter your company.
Please enter your department.
Please enter your function.
Please enter your street.
Please enter your postal code and city.
Please enter your e-mail address.

Please send me via email


Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470. 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contact
Visit us

Fresenius SE & Co. KGaA

Fresenius uses cookies on this website to enhance the user experience and provide the best possible service. By continuing to browse the website, you consent to our use of cookies.

Learn more
OK